Sotagliflozin, initiated 1 week after the last surgery, showed target‐engagement evidenced by glucosuria, 9 mmHg lower SBP, temporal reduction in body weight and GFR, and 30% higher plasma GLP1. The gene discussed is GCG; the disease is Glycosuria.